FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4207059242> ?p ?o ?g. }

• W4207059242 abstract "Sepsis is a syndrome with high mortality, which seriously threatens human health. During the pandemic of coronavirus disease 2019 (COVID-19), some severe and critically ill COVID-19 patients with multiple organ dysfunction developed characteristics typical of sepsis and met the diagnostic criteria for sepsis. Timely detection of cytokine storm and appropriate regulation of inflammatory response may be significant in the prevention and treatment of sepsis. This study evaluated the efficacy and safety of specific interleukin (IL)-1 inhibitors, specific IL-6 inhibitors, and GM-CSF blockades in the treatment of COVID-19 (at the edge of sepsis) patients through systematic review and meta-analysis.A literature search was conducted on PubMed, EMBASE, Clinical Key, Cochrane Library, CNKI, and Wanfang Database using proper keywords such as SARS-CoV-2, Corona Virus Disease 2019, COVID-19, anakinra, tocilizumab, siltuximab, sarilumab, mavrilimumab, lenzilumab, and related words for publications released until August 22, 2021. Other available resources were also used to identify relevant articles. The present systematic review was performed based on PRISMA protocol.Based on the inclusion and exclusion criteria, 43 articles were included in the final review. The meta-analysis results showed that tocilizumab could reduce the mortality of patients with COVID-19 (at the edge of sepsis) [randomized controlled trials, RCTs: odds ratio (OR) 0.71, 95%CI: 0.52-0.97, low-certainty evidence; non-RCTs: risk ratio (RR) 0.68, 95%CI: 0.55-0.84, very low-certainty evidence) as was anakinra (non-RCTs: RR 0.47, 95%CI: 0.34-0.66, very low-certainty evidence). Sarilumab might reduce the mortality of patients with COVID-19 (at the edge of sepsis), but there was no statistical significance (OR 0.65, 95%CI: 0.36-1.2, low-certainty evidence). For safety outcomes, whether tocilizumab had an impact on serious adverse events (SAEs) was very uncertain (RCTs: OR 0.87, 95%CI: 0.38-2.0, low-certainty evidence; non-RCTs 1.18, 95%CI: 0.83-1.68, very low-certainty evidence) as was on secondary infections (RCTs: OR 0.71, 95%CI: 0.06-8.75, low-certainty evidence; non-RCTs: RR 1.15, 95%CI: 0.89-1.49, very low-certainty evidence).This systematic review showed that tocilizumab, sarilumab, and anakinra could reduce the mortality of people with COVID-19 (at the edge of sepsis), and tocilizumab did not significantly affect SAEs and secondary infections. The current evidence of the studies on patients treated with siltuximab, mavrilimumab, and lenzilumab is insufficient. In order to establish evidence with stronger quality, high-quality studies are needed. Systematic Review Registration: PROSPERO (https://www.crd.york.ac.uk/prospero/), identifier CRD42020226545." @default.
• W4207059242 created "2022-01-26" @default.
• W4207059242 creator A5002384071 @default.
• W4207059242 creator A5017616762 @default.
• W4207059242 creator A5018863416 @default.
• W4207059242 creator A5036681067 @default.
• W4207059242 creator A5050390575 @default.
• W4207059242 creator A5059855262 @default.
• W4207059242 creator A5081675173 @default.
• W4207059242 date "2022-01-21" @default.
• W4207059242 modified "2023-09-29" @default.
• W4207059242 title "Specific Interleukin-1 Inhibitors, Specific Interleukin-6 Inhibitors, and GM-CSF Blockades for COVID-19 (at the Edge of Sepsis): A Systematic Review" @default.
• W4207059242 cites W2089785792 @default.
• W4207059242 cites W2280404143 @default.
• W4207059242 cites W2282181907 @default.
• W4207059242 cites W2936019126 @default.
• W4207059242 cites W2970684805 @default.
• W4207059242 cites W2976387938 @default.
• W4207059242 cites W2998853022 @default.
• W4207059242 cites W3001118548 @default.
• W4207059242 cites W3009859788 @default.
• W4207059242 cites W3016771699 @default.
• W4207059242 cites W3021940537 @default.
• W4207059242 cites W3023600945 @default.
• W4207059242 cites W3024698409 @default.
• W4207059242 cites W3026301261 @default.
• W4207059242 cites W3028866422 @default.
• W4207059242 cites W3035293132 @default.
• W4207059242 cites W3037107462 @default.
• W4207059242 cites W3038241707 @default.
• W4207059242 cites W3041464116 @default.
• W4207059242 cites W3042042989 @default.
• W4207059242 cites W3043831218 @default.
• W4207059242 cites W3044857285 @default.
• W4207059242 cites W3045087338 @default.
• W4207059242 cites W3081211513 @default.
• W4207059242 cites W3081502886 @default.
• W4207059242 cites W3084608615 @default.
• W4207059242 cites W3088646954 @default.
• W4207059242 cites W3089421034 @default.
• W4207059242 cites W3091337946 @default.
• W4207059242 cites W3093016541 @default.
• W4207059242 cites W3093017985 @default.
• W4207059242 cites W3093837118 @default.
• W4207059242 cites W3096105852 @default.
• W4207059242 cites W3102488036 @default.
• W4207059242 cites W3105103693 @default.
• W4207059242 cites W3108571027 @default.
• W4207059242 cites W3108844335 @default.
• W4207059242 cites W3109028740 @default.
• W4207059242 cites W3110685620 @default.
• W4207059242 cites W3110735907 @default.
• W4207059242 cites W3117169676 @default.
• W4207059242 cites W3117582084 @default.
• W4207059242 cites W3118867763 @default.
• W4207059242 cites W3121047208 @default.
• W4207059242 cites W3128616497 @default.
• W4207059242 cites W3128695597 @default.
• W4207059242 cites W3128941599 @default.
• W4207059242 cites W3130126061 @default.
• W4207059242 cites W3133478102 @default.
• W4207059242 cites W3133691270 @default.
• W4207059242 cites W3133830113 @default.
• W4207059242 cites W3134674969 @default.
• W4207059242 cites W3136776366 @default.
• W4207059242 cites W3137226291 @default.
• W4207059242 cites W3158725921 @default.
• W4207059242 cites W3163919225 @default.
• W4207059242 cites W3164201440 @default.
• W4207059242 cites W3176830244 @default.
• W4207059242 cites W3180304388 @default.
• W4207059242 cites W3198379317 @default.
• W4207059242 cites W4294215472 @default.
• W4207059242 doi "https://doi.org/10.3389/fphar.2021.804250" @default.
• W4207059242 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35126138" @default.
• W4207059242 hasPublicationYear "2022" @default.
• W4207059242 type Work @default.
• W4207059242 citedByCount "15" @default.
• W4207059242 countsByYear W42070592422022 @default.
• W4207059242 countsByYear W42070592422023 @default.
• W4207059242 crossrefType "journal-article" @default.
• W4207059242 hasAuthorship W4207059242A5002384071 @default.
• W4207059242 hasAuthorship W4207059242A5017616762 @default.
• W4207059242 hasAuthorship W4207059242A5018863416 @default.
• W4207059242 hasAuthorship W4207059242A5036681067 @default.
• W4207059242 hasAuthorship W4207059242A5050390575 @default.
• W4207059242 hasAuthorship W4207059242A5059855262 @default.
• W4207059242 hasAuthorship W4207059242A5081675173 @default.
• W4207059242 hasBestOaLocation W42070592421 @default.
• W4207059242 hasConcept C126322002 @default.
• W4207059242 hasConcept C156957248 @default.
• W4207059242 hasConcept C168563851 @default.
• W4207059242 hasConcept C2776478404 @default.
• W4207059242 hasConcept C2777178219 @default.
• W4207059242 hasConcept C2778384902 @default.
• W4207059242 hasConcept C2779134260 @default.
• W4207059242 hasConcept C2779559532 @default.
• W4207059242 hasConcept C2781228260 @default.
• W4207059242 hasConcept C3008058167 @default.
• W4207059242 hasConcept C524204448 @default.

• next